NCT05523167

A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

← 임상시험 허브

레지스트리 요약

진행 상태: 완료 (COMPLETED)
질환/조건: Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome
시험 유형: 중재 연구 (INTERVENTIONAL)
단계: Phase 2, Phase 3
목적: 치료
중재 유형: 생물학적 제제, 기타
개입·치료: EFG PH20 SC, PBO
Lead Sponsor: argenx (산업계)

캐시 시각: 2026-07-25 04:09:41

ClinicalTrials.gov에서 보기

요약

This study's purpose is to measure the treatment response from efgartigimod PH20 SC compared with placebo in participants with Idiopathic Inflammatory Myopathy (IIM). Participants with the IIM subtypes of dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), or certain other subtypes of polymyositis (PM; including antisynthetase syndrome \[ASyS\]) will be included in the study. Treatment response will be measured by Total improvement score (TIS).

문의

이 시험 기반 리포트·메디컬라이팅이 필요하시면 문의해 주세요.

리포트 문의 메디컬라이팅 문의 맞춤 리서치 리포트